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ABSTRACT 
 
Lee Wade Hutson: Region-Specific Contribution of the VTA to Heroin-Induced Conditioned 
Immunomodulation 
(Under the direction of Donald T. Lysle) 
 
Dopamine receptor stimulation is critical for heroin-conditioned immunomodulation; 
however, it is unclear whether the ventral tegmental area (VTA) contributes to this 
phenomenon. Hence, rats received repeated pairings of heroin with placement into a distinct 
environmental context. At test, they were re-exposed to the previously heroin-paired 
environment followed by systemic lipopolysaccharide treatment to induce an immune 
response. Bilateral GABA agonist-induced neural inactivation of the anterior, but not the 
posterior VTA, prior to context re-exposure inhibited the ability of the heroin-paired 
environment to suppress peripheral nitric oxide and tumor necrosis factor-α expression, 
suggesting a role for the anterior VTA in heroin-conditioned immunomodulation. 
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CHAPTER I: INTRODUCTION 
It was long believed that the nervous and immune system functioned independently of 
one another; however, this idea was challenged by Ader and Cohen in 1975 when a 
Pavlovian associative learning model was used to demonstrate for the first time that a 
previously neutral stimulus can acquire immune altering effects after pairing with an 
immunomodulatory drug. In this study, Ader and Cohen paired the immunosuppressive drug 
cyclophosphamide with saccharin. Results revealed no evidence of an immunomodulatory 
effect from exposure to saccharin among control animals, however an immunosuppressive 
effect was observed among conditioned animals when exposed to saccharin, indicating that 
saccharin had acquired immune altering properties similar to those of cyclophosphamide. 
Subsequent studies conducted by Ader and colleagues further demonstrated conditioned 
immunomodulatory effects on the autoimmune disease systemic lupus erythematosus (Ader 
and Cohen 1982), humoral immunity (Ader, Cohen et al. 1982; Ader, Kelly et al. 1993), and 
cell-mediated immunity (Ader and Cohen 1992), which established psychoneuroimmunology 
as a new field of study.  
Building upon the work of Ader and Cohen, others began to investigate the neural 
circuitry involved in conditioned immunomodulation. Brain regions of interest were 
identified based on previous research that mapped out a basic neural circuit of the 
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conditioned taste aversion model (Pacheco-Lopez, Niemi et al. 2005), which was used to 
model conditioned immunosuppression by pairing saccharin with cyclosporine A, an 
immunologic drug. Excitotoxic lesions were performed in brain after the acquisition phase. 
Results revealed that disruption of insular cortex and ventromedial hypothalamus, but not the 
amygdala, signaling prevented the expression of conditioned immunosuppression of 
lymphocyte proliferation, IL-2, and interferon-γ (Pacheco-Lopez, Niemi et al. 2005).  
In addition to findings indicating that the effects of immunologic drugs are capable of 
producing conditioned immunosuppression when paired with previously neutral stimuli, 
research suggests that opiates directly affect the immune system’s ability to defend against 
infection (Luttgens 1949; Hussey and Katz 1950; Bussiere, Adler et al. 1993; Friedman and 
Eisenstein 2004). In particular, opioid administration has detrimental health consequences in 
addition to the possible development of addictive behaviors and dependence. Clinical studies 
have revealed abnormalities in basic immune parameters in heroin users, including a 
decrease in circulating lymphocytes, natural killer cell activity, cytokine production, and 
antibody-dependent cellular cytotoxicity (Nair, Navaratnam et al. 1986; Govitrapong, 
Suttitum et al. 1998; Olson, Zabetian et al. 2005; Yardeni, Beilin et al. 2008). Several 
immune parameters that are critical for innate immune responses are altered by opioid use, 
such as the expression of inducible nitric oxide synthase (iNOS) (Lysle and How 2000) and 
the production of the proinflammatory cytokines, tumor necrosis factor-α (TNF-α) and 
interleukin-1β (IL-1β) (Chao, Molitor et al. 1993; Pacifici, di Carlo et al. 2000). Thus, these 
studies suggest that chronic opioid administration results in an impaired ability to defend 
against infectious disease (Theodorou and Haber 2005).  
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Interestingly, opioid-induced immunosuppression is mediated by the central nervous 
system (Shavit, Depaulis et al. 1986; Fecho, Maslonek et al. 1996; Lysle, Hoffman et al. 
1996), and based on the previously described studies on conditioned immunomodulation, the 
immunosuppressive effects of exogenous opioid administration cannot exclusively be 
attributed to acute pharmacological effects on physiology. Early research from our laboratory 
has shown that the immune altering effects of opioids, including those of morphine and 
heroin, can be conditioned to environmental stimuli by pairing opioid administration with 
exposure to a distinct environmental context. As a result, a morphine-paired context (CS) can 
acquire immune altering effects. For example, following conditioning sessions during which 
morphine injections were paired with a distinct context, rats exhibited significant reductions 
in mitogenic responsiveness of lymphocytes, natural killer cell activity, and interleukin-2 
production when re-exposed to the distinct context in a drug free state, demonstrating for the 
first time morphine-conditioned immunosuppression (Coussons, Dykstra et al. 1992). It was 
later discovered that dopamine and glutamate are involved in conditioned 
immunomodulation (Hsueh, Kuo et al. 1999; Kuo, Chen et al. 2001), which led to our 
laboratory investigating the contributions of specific neurotransmitters to morphine- and 
heroin-conditioned immunosuppression. Findings from our laboratory demonstrated that 
dopamine receptor activity was necessary for the expression of conditioned immune 
alterations. Furthermore, administration of a D1-like receptor antagonist prior to re-exposure 
to the conditioned stimulus prevented the suppression of natural killer cell activity (Saurer, 
Ijames et al. 2008). Similar immunomodulatory effects have also been demonstrated with 
heroin (Fecho and Lysle 2000; Lysle and Ijames 2002; Saurer, Ijames et al. 2008). 
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Emerging evidence suggests that a limbic neural circuit mediates the expression of 
heroin-induced conditioned immune alterations, and this circuit likely includes the ventral 
tegmental area (VTA).  In support of this, either GABA agonist-induced neural inactivation 
of, or dopamine D1-like receptor antagonism in, the basolateral amygdala (BLA) blocks 
heroin-induced conditioned immunosuppression (Szczytkowski and Lysle 2008; 
Szczytkowski and Lysle 2010). Moreover, unilateral dopamine D1-like receptor antagonism 
in the BLA coupled with contralateral NMDA glutamate receptor antagonism in the nucleus 
accumbens shell (NAc shell) significantly attenuates the expression of heroin-conditioned 
immunosuppression. In contrast, ipsilateral manipulation of the same brain regions fails to 
disrupt heroin-conditioned immunomodulation (Szczytkowski, Fuchs et al. 2011).  These 
findings suggest that dopamine in the BLA, via the stimulation of D1-like receptors, is 
necessary for obligatory intrahemispheric interactions between the BLA and the NAc in the 
control of heroin-conditioned immune alterations.   
The critical source of dopamine involved in heroin-conditioned immunomodulation has 
not been investigated even though the VTA is the likely candidate. Opioid administration 
results in the disinhibition of dopaminergic projection neurons and the release of dopamine at 
terminal regions via the stimulation of µ receptors on VTA GABAergic inter- and projection 
neurons. Similarly, heroin-associated stimuli increase the activity of VTA neurons (Kiyatkin 
and Rebec 2001). Recently, investigations have focused on elucidating the function of 
various subregions of the VTA. Studies suggest that the VTA is a heterogeneous structure 
with distinct subregions differentially affecting drug-induced behaviors. For example, µ 
opioid receptor antagonism in the anterior, but not posterior, VTA prevents the acquisition of 
cocaine-induced conditioned place preference (Soderman and Unterwald 2008). Furthermore, 
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rats self-administer the GABAA antagonist picrotoxin into the anterior, but not the posterior, 
VTA (Ikemoto, Kohl et al. 1997). Furthermore, a study utilizing retrograde tracing 
techniques determined that dopaminergic efferents from the VTA to BLA originate in the  
anterior VTA (Ford, Mark et al. 2006), whereas a large proportion of dopaminergic 
projections from the posterior VTA terminate in the NAc (Ikemoto 2007). Based on these 
findings and the importance of dopamine signaling in the BLA in conditioned 
immunosuppression (Szczytkowski and Lysle 2008; Szczytkowski and Lysle 2010; 
Szczytkowski, Fuchs et al. 2011), we hypothesized that the functional integrity of the 
anterior, but not posterior, VTA is necessary for the expression of heroin-conditioned 
immunomodulation.  
The present study selectively targeted the anterior or posterior VTA in order to evaluate 
the distinct contributions of these VTA subregions to the expression of heroin-induced 
conditioned immunomodulation. Rats underwent a conditioning procedure which consisted 
of repeated pairings of heroin administration with placement into a distinct environment. 
Following the conditioning regimen, rats received microinfusions of saline vehicle or a 
cocktail of the GABAB/GABAA agonists, baclofen/muscimol into the anterior or posterior 
VTA in order to temporarily inactivate these VTA subregions. Rats were then re-exposed to 
the previously heroin-paired environment in a drug free state. Six hours following re-
exposure, rats received a subcutaneous injection of lipopolysaccharide (LPS) to induce an 
immune response. In order to assess CS-induced alterations in immune status, the effects of 
these manipulations were examined on the expression of the proinflammatory mediators, 
iNOS and TNF-α, in the spleen and/or plasma.     
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CHAPTER II: MATERIALS AND METHODS 
Animals 
Male Lewis rats, weighing 225–250 g, were purchased from Charles River Laboratories 
(Raleigh, NC, USA). Upon arrival, animals were housed individually in plastic cages in a 
colony room with a reversed light-dark (12-h) cycle maintained through artificial 
illumination. Animals were allowed access to food and water ad libitum throughout the 
experiment except for the time spent in the conditioning chambers when food and water were 
not available. All animals were given a 2-week habituation period before the start of 
experimental manipulations and were handled regularly during this time. All procedures 
described were approved by the IACUC of the University of North Carolina at Chapel Hill 
and conformed to National Institutes of Health (NIH) Guidelines on the Care and Use of 
Laboratory Animals. 
Drug Administration 
Heroin (diacetylmorphine) was obtained from NIDA (Bethesda, MD, USA) and dissolved in 
0.9% sterile saline. Heroin was administered subcutaneously at a dose of 1 mg/kg. This dose 
was selected based on prior experiments in our laboratory showing that it induces 
conditioning and alters LPS-induced iNOS and TNF-α mRNA expression in spleen tissue 
(Lysle and How 2000; Lysle and Ijames 2002; Szczytkowski and Lysle 2007)
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Surgical Procedures 
Animals were fully anesthetized with 0.35 mL intramuscular injections of 1:1 (vol:vol) 
ketamine hydrochloride (100 mg/mL) mixed with xylazine (20 mg/mL) and placed into the 
stereotaxic apparatus. Animals were implanted bilaterally with 26-gauge guide cannulae 
(Plastics One, Roanoke, VA, USA). The cannulae were angled at 10° and directed towards 
the anterior VTA (AP −5.0, ML ± 2.2, DV −6.1 mm, relative to bregma) or posterior VTA 
(AP −6.0, ML ± 2.05, DV −6.3 mm, relative to bregma). Animals were given a 2-week post-
surgical recovery period before the start of conditioning trials.  
Conditioning Procedure 
All animals received five conditioning sessions in standard conditioning chambers 
(BRS/LVE, Laurel, MD, USA).  Chambers were fitted with a metal grid floor design and 
cedar bedding to create an environment distinct from that of the home cage and to provide 
both olfactory and tactile cues for conditioning. Artificial noise machines were used to 
minimize background noise. All conditioning took place during the dark phase of the light 
cycle in a room separate from the animal colony and the conditioning chambers were kept 
dark to minimize effects on circadian rhythms. On each conditioning day, a subcutaneous 
injection of heroin (1 mg/kg) was administered immediately prior to placement into the 
chamber for 60-min. Training sessions were separated by 48 h.  
Test of Heroin-Conditioned Immunomodulation 
Six days following the final conditioning session, animals received bilateral microinfusions 
of saline vehicle (0.3 μL per hemisphere) or baclofen/muscimol (0.3/0.03 nmol per 0.3 μL 
per hemisphere) into the anterior or posterior VTA. Injectors extended 3 mm beyond the tip 
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of the guide cannula. Injections were delivered over 1 min, and the injectors were left in 
place for 1 min after the injection to allow for proper diffusion of fluid away from the 
infusion site. Thirty minutes later, the rats were re-exposed to the previously heroin-paired 
conditioning chamber or remained in their home cages (home cage control groups) for 60 
min.  Heroin was not administered on the test day in order to isolate the effect of the CS on 
immune responses. After the 60-min time period, all rats received a subcutaneous injection of 
LPS (1000 μg/kg) and were immediately returned into their home cages. LPS, a component 
of the cell wall of Gram negative bacteria, was used to induce iNOS and TNF-α production. 
Six hours after LPS administration, all animals were euthanized.  The 6-h time point was 
selected based on previous research in our laboratory showing maximal iNOS induction 6 h 
following LPS administration (Lysle and How 2000). 
Histology 
Samples of spleen and blood were collected for analysis. Spleen samples were either stored 
in an Ambion® RNA Later solution or Roche complete protease inhibitor cocktail solution. 
To confirm proper cannula placement, Alcian blue dye was infused via the cannula. Brains 
were then extracted and post-fixed in a 4% paraformaldehyde solution. Following fixation 
the brains were transferred to a 30% sucrose solution for cryoprotection and then frozen at 
− 80 °C until further analysis. Coronal sections (40 μm) were taken and stained with cresyl 
violet for verification of cannula placement. The data of animals with cannula placement 
outside of the targeted region were removed from subsequent data analyses. 
Real-Time qRT-PCR 
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To determine iNOS and TNF- α expression, real time RT-PCR was performed on tissue 
samples from the spleen. Total RNA was extracted from a section of each of the tissues using 
TRI-Reagent (Molecular Research Center, Cincinnati, OH), a modification of the original 
method described by Chomczynski and Sacchi (1987). RNA was quantified 
spectrophotometrically (GeneQuant II, Pharmacia-Biotech, Piscataway, NJ, USA). Reverse 
transcription was performed using Oligo(dT)18 primer and Moloney Murine Leukemia Virus-
Reverse transcriptase following the protocol of the Advantage RT-for-PCR Kit from 
Clontech (Palo Alto, CA, USA).  Specific products from the PCR reaction were detected 
with Universal ProbeLibrary Probes (Roche, Indianapolis, IN). PCR amplifications were 
performed using standard protocols, the LightCycler TaqMan Master Real-Time PCR Kit, 
and the LightCycler II instrument (Roche, Indianapolis, IN). A master mix containing all 
reaction components was prepared and then 20 µl of cDNA with master mix was placed in 
glass capillary tubes designed for use in the LightCycler II system. Primers and probes for 
immune parameters were as follows: (iNOS) 5′-TGAGGATTACTTCTTCCAGCTCA-3′ and 
5′-TGGGTGTCAGAGTCTTGTGC-3′, using probe #25; (TNF-α) 5’-
GGGCCTCCAGAACTCCAG-3’ and 5’-GAGCCATTTGGGAACTTCT-3’, using probe 
#98.  Primers were synthesized by the Nucleic Acids Core Facility (Lineberger Cancer 
Center, UNC-Chapel Hill). Copy numbers were generated based on an internal standard 
curve.  Amplifications were carried out for 45 cycles and curves showing fluorescence at 
each cycle were determined by the computer software (Roche). Samples were pre-incubated 
for 10 min at 95
o 
C to activate the Fast-Start Taq DNA polymerase. The cycle temperatures 
were 95 and 60 °C and the cycle times were 10 and 30 s for the denaturing and 
annealing/extending, respectively. Fluorescence level was determined at the end of the 
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extending phase for each cycle of PCR. A final cooling phase was carried out at 40° C for 30 
s. The analysis of the fluorescence in standards and samples over the course of 45 cycles was 
used to derive the number of copies of the target molecule in each sample. Additionally, 
assessments of housekeeping gene expression, L13A, were made to verify comparable RNA 
quality of among samples. L13A primers were 5′-CCCTCCACCCTATGACAAGA-3′ and 
5′-GGTACTTCCACCCGACCTC-3′, using probe #74.  The data are expressed as copy 
Nitrite/Nitrate Assay  
The nitrite/nitrate concentration in plasma samples was assessed using the Greiss reagent 
assay described previously (Szczytkowski and Lysle 2007). Briefly, 6 μl of plasma was 
diluted in 44 μl of dH2O, and the sample was incubated in the dark for 90 min with 10 μl of 
nitrate reductase (1.0 U/ml), 20 μl of 0.31M phosphate buffer (pH 7.5), 10 μl of 0.86mM 
NADPH (Sigma), and 10 μl of 0.11mM flavin adenine dinucleotide in individual wells of a 
96-well plate. Next, 200 ml of Greiss reagent, consisting of a 1:1 (v/v) solution 1% 
sulfanilamide in 5.0% phosphoric acid and 0.1% N-(1-napthyl) ethyl-enedamine 
dihydrochloride in distilled water, was added to the samples. The color was allowed to 
develop for 10 min at room temperature, after which, the absorbance was determined using a 
spectrophotometer set at 550 nm. All reactions were carried out in triplicate. The total 
micromolar concentration of nitrite was determined for each sample based on a standard 
curve. Recovery of nitrate is greater than 95% using this assay. 
 
ELISA 
To assess TNF-α protein expression, protein was extracted from a section of each 
homogenized tissue using freeze/thaw lysis in tris-buffer containing antiproteinases. Protein 
was quantified spectrophotometrically (Bio-Tek, Model EL312 kinetic reader, Winooski, 
VT, USA) using Bio-Rad protein dye. To account for variability in tissue size, samples were 
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normalized per unit protein based on the results of the spectrophotometric analysis. 
Invitrogen (Carlsbad, CA) rat TNF-α ELISA test kits were used to determine the levels of 
TNF-α protein in each tissue sample. Briefly, samples and standards were added to microtiter 
wells coated with TNF-α antibody and incubated at room temperature for how long. Wells 
were washed extensively then incubated with biotinylated antibody. After a second wash, the 
wells were incubated with Streptavidin-HRP and exposed to a chromagen substrate solution 
for 30 min.  Absorbance at 450 nm was measured with a Bio-Tek (Winooski, VT) Model 
EL312 kinetic reader. A standard curve was obtained by plotting the absorbance against the 
concentrations of supplied standards.  
 
Statistical Analysis 
Two-way analysis of variance was performed on all data sets. Significant effects were 
followed-up using Tukey’s post hoc tests. All analyses were conducted with alpha set 
at p < 0.05. Only significant interactions and main effects are reported. 
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CHAPTER III: RESULTS 
Anterior VTA Inactivation  
 
Figure 1A shows the effect of anterior VTA inactivation on LPS-induced heroin-
conditioned iNOS mRNA expression in spleen tissue following exposure to the heroin-paired 
context or the home cage. The ANOVA of iNOS mRNA copy numbers revealed a significant 
context by treatment interaction effect [F(1,16) = 14.882, P < 0.005] and a significant main 
effect of context [F(1,16) = 5.975, P < 0.05]. Tukey’s post-hoc analyses revealed that saline-
treated rats exposed to the heroin-paired context exhibited a reduction in iNOS mRNA 
expression compared to that in the home cage (p = 0.001). Conversely, rats that received 
intra-VTA microinjections of baclofen/muscimol failed to exhibit differences in iNOS 
mRNA expression after exposure to the previously heroin-paired environment or the home 
cage. There were also no differences across groups in housekeeping gene expression (data 
not shown). 
Figure 1B shows the effect of anterior VTA inactivation on LPS-induced plasma 
nitrate/nitrite levels. The ANOVA of nitrate/nitrite levels revealed a significant context by 
treatment interaction effect [F(1,16) = 5.831, P < 0.05]. Tukey’s post-hoc analyses revealed 
that saline-treated rats exposed to the heroin-paired context exhibited a reduction in iNOS 
mRNA expression compared to that in the home cage (p = .032). Conversely, rats that 
received intra-VTA microinjections of baclofen/muscimol failed to exhibit differences in
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iNOS mRNA expression after exposure to the two contexts and compared to the saline-
treated home cage control group.   
 A                                                                            B 
 
Figure 1: (A) Effects of treatment on LPS-induced expression of iNOS mRNA as 
determined by real-time RT-PCR. The data are expressed as iNOS copy number per 10ng 
cDNA based on a standard curve using Roche LightCycler software. (B) Effects of treatment 
on LPS-induced expression of nitrate/nitrite serum levels as determined by Greiss Reagent 
Assay. The data are expressed as the mean micromolar concentration of nitrite/nitrate. The 
error bars represent the standard error of the mean. 
 
 
Figure 2 shows the effect of anterior VTA inactivation on LPS-induced TNF-α 
mRNA and protein expression. The ANOVA found a significant context by treatment 
interaction effect on TNF-α mRNA expression [F(1,16) = 6.464 P < 0.05] and protein levels 
[F(1,15) = 4.578, P < 0.05], as well as a significant main effect of exposure to the context 
[F(1,16) = 8.585, P < 0.05] on protein levels.  Tukey’s post-hoc analyses revealed that 
saline-treated rats exposed to the heroin-paired context exhibited a reduction in TNF-α 
mRNA expression (p = 0.037) and protein levels (p = 0.007) compared to animals re-exposed 
to home cages. Animals that underwent anterior VTA inactivation prior to CS re-exposure 
showed no significant difference in LPS-induced TNF-α mRNA expression or protein levels 
compared to anterior VTA inactivation controls. No differences in housekeeping gene 
expression were observed across groups (data not shown). 
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Figure 2: (A) Effects of treatment on LPS-induced expression of TNF-α mRNA 
determined by real-time RT-PCR. The data are expressed as TNF-α copy number per 10ng 
cDNA based on a standard curve using Roche LightCycler software. (B) Effects of treatment 
on LPS-induced production of TNF-α protein determined by ELISA. The data are expressed 
as picograms of protein per ml. The error bars represent the standard error of the mean. 
 
Posterior VTA Inactivation 
 
Figure 3A shows the effect of posterior VTA inactivation on LPS-induced iNOS 
mRNA expression. Analysis revealed no significant context by treatment interaction in the 
posterior VTA; however, the ANOVA revealed a significant main effect of re-exposure to 
the CS on iNOS mRNA expression [F(1,15) = 20.327, P < 0.0001].  
Figure 3B shows the effect of posterior VTA inactivation on LPS-induced levels of 
nitrate/nitrite in blood plasma. The ANOVA revealed a significant main effect of re-exposure 
to the CS on nitrate/nitrite plasma levels [F(1,15) = 7.284, P < 0.05] and no significant 
context by treatment interaction. 
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Figure 3: (A) Effects of treatment on LPS-induced expression of iNOS mRNA as 
determined by real-time RT-PCR. The data are expressed as iNOS copy number per 10ng 
cDNA based on a standard curve using Roche LightCycler software. (B) Effects of treatment 
on LPS-induced expression of nitrate serum levels as determined by Greiss Reagent Assay. 
The data are expressed as the mean micromolar concentration of nitrite/nitrate. The error bars 
represent the standard error of the mean. 
 
 
Figure 4A shows the effect of posterior VTA inactivation on LPS-induced TNF-α 
mRNA expression. The ANOVA of TNF-α mRNA expression revealed a nearly significant 
main effect of re-exposure to the CS [F(1,14) = 4.224, P = 0.059]. Most notably, re-exposure 
to the heroin-paired CS following inactivation of the posterior VTA does not attenuate the 
immunosuppressive effect of the CS on TNF-α mRNA levels (p < 0.05).  
Figure 4B shows the effect of posterior VTA inactivation on LPS-induced TNF-α 
protein levels. The ANOVA of TNF-α protein levels revealed a significant main effect of re-
exposure to the CS [F(1,15) = 14.682, P < 0.005] and drug treatment 
[F(1,15) = 10.126, P < 0.01], and there was no significant context by treatment interaction.  
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Figure 4: (A) Effects of treatment on LPS-induced expression of TNF-α mRNA 
determined by real-time RT-PCR. The data are expressed as TNF-α copy number per 10ng 
cDNA based on a standard curve using Roche LightCycler software. (B) Effects of treatment 
on LPS-induced production of TNF-α protein determined by ELISA. The data are expressed 
as pictograms of protein per ml. The error bars represent the standard error of the mean. 
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CHAPTER IV: DISCUSSION 
 
In the present study, neural activity in the anterior or posterior VTA was inhibited 
using GABA agonists prior to re-exposure to a heroin-paired environmental context in order 
to determine if subregions of the VTA play differential roles in the expression of heroin-
conditioned immune alterations. Anterior VTA neuronal inactivation disrupted the 
immunosuppressive effects of the heroin-paired context on LPS-induced TNF-α and iNOS 
expression.  This suggests that the functional integrity of the anterior VTA is necessary for 
the expression of heroin-induced conditioned immune suppression of proinflammatory 
mediators.  In contrast, posterior VTA inactivation failed to alter heroin-paired context-
induced alterations of proinflammatory mediators, suggesting that the posterior VTA does 
not play a critical role in this phenomenon under the current experimental conditions. These 
findings expand our understanding of the neural circuitry involved in heroin-conditioned 
immunomodulation by identifying a source of dopamine that alters the activity of several 
other brain regions within this circuitry. 
Previous research in our laboratory suggests that dopamine regulates multiple 
elements of the neural circuitry underlying conditioned immunomodulation. In support of 
this, inactivation of the BLA and blockade of dopamine D1-like receptors within the BLA 
prevents the suppressive effect of the heroin-associated context on iNOS induction and on 
the expression of TNF-α and IL-1β in spleen and liver tissue (Szczytkowski and Lysle 2008; 
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Szczytkowski and Lysle 2010). Antagonism of dopamine D1-like receptors in the NAc shell 
blocks the expression of morphine-induced conditioned immune alterations (Saurer, James et 
al. 2008). Given that opioid-conditioned immunosuppression is a drug-like conditioned 
response, D1-like receptor stimulation in the NAc shell may also be required for 
immunosuppression in a morphine- or heroin-paired context. According to a recent 
functional disconnection study from our laboratory (Szczytkowski, Fuchs et al. 2011), the 
NAc plays a critical role in heron-conditioned immunomodulation as an element of a larger 
VTA-BLA-NAc circuit. In that study, rats received unilateral administration of the D1-like 
dopamine antagonist, SCH23390, in the BLA in combination with unilateral administration 
of the NMDA or AMPA/kinate antagonist, into the ipsilateral or contralateral NAc on test 
day.  Contralateral manipulation (i.e., disconnection) of the VTA-BLA-NAc circuit inhibited 
the heroin-conditioned immunosuppression of iNOS and TNF-α in the spleen.  Conversely, 
the ipsilateral manipulation, which left intrahemispheric information processing between the 
BLA and NAc intact in one hemisphere, failed to alter proinflammatory responses.  Given 
that the VTA is one of the primary sources of dopamine to the BLA (Rosenkranz and Grace 
1999), these findings suggest that serial information processing via a VTA-BLA-NAc circuit 
is necessary for the expression of heroin-conditioned immunomodulation.   
Remarkably, the effects of VTA inactivation on conditioned immunomodulation 
depended on the subregion of the VTA manipulated in the present study, consistent with 
studies demonstrating similar functional differences between subregions of the VTA  (Lee, 
Guttilla et al. 2007). For example, rats self-administer the GABAA receptor antagonist 
picrotoxin into the anterior, but not the posterior, VTA (Ikemoto, Murphy et al. 1997). This 
effect may be mediated by the disinhibition of dopaminergic neurons in the anterior VTA and 
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subsequent dopamine release in the NAc because picrotoxin administration into the anterior 
VTA increases dopamine overflow in the NAc (Ikemoto, Kohl et al. 1997). Furthermore, 
microinfusions of the GABAA agonist muscimol into the anterior, but not posterior VTA, 
significantly reduced cocaine self-administration.  
Functional differences between anterior and posterior VTA subregions likely reflect 
differences in neurochemistry and connectivity between these VTA subregions (Johnson & 
North 1992; Swanson, 1982).  For example, the anterior and posterior VTA contain different 
proportions of dopaminergic and glutamatergic neurons and GABAergic interneurons, with a 
higher proportion of GABAergic interneurons and dopaminergic neurons located in the 
anterior VTA and posterior VTA, respectively (Olson, Zabetian et al. 2005; Yamaguchi, 
Sheen et al. 2007).  Interestingly, VTA efferents to the BLA are localized in the anterior 
VTA, which was verified using retrograde tracing techniques (Ford, Mark et al. 2006; 
Ikemoto 2007). Conversely, dopamine neurons from the posterior VTA project to NAc core 
and medial shell, with a significant amount of overlap in projections between the anterior and 
posterior VTA. Given the previously discussed importance of dopamine in the BLA in 
heroin-conditioned immunosuppression, we hypothesized that the anterior, but not posterior, 
VTA would be important in the expression of heroin-conditioned immunomodulation.  The 
results of the present study support this hypothesis. Our findings also suggest that projections 
from the posterior VTA, which include projections to the NAc shell and core, are not critical 
for the expression of the observed heroin-conditioned suppression of proinflammatory 
mediators. On the other hand, dopaminergic signaling to the NAc originating from the 
anterior VTA may play a role in heroin-conditioned immunosuppression. Importantly, 
interactions between the VTA, NAc, and BLA appear to be complex, as dopamine release in 
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the NAc is proposed to be regulated by BLA glutamatergic efferents (Jones, Day et al. 2010). 
Consistent with this, temporary neural inactivation of the BLA results in decreased 
discriminative stimulus-induced evoked NAc dopamine release. In addition, BLA 
inactivation has no effect on NAc dopamine release following VTA stimulation, indicating 
that the BLA does not modulate dopamine release indirectly through the VTA (Howland, 
Taepavarapruk et al. 2002). Taken together, these previous findings suggest that 
dopaminergic signaling from the anterior VTA may result in dopamine release at the terminal 
level in the NAc. Future studies will need to test this hypothesis by examining the effects of 
dopamine antagonism in the NAc on conditioned immunosuppression. 
The present study enhances our understanding of the neural circuit involved in the 
conditioned effects of heroin on immune function by demonstrating that the anterior VTA is 
necessary for the heroin-conditioned suppression of iNOS induction and expression of TNF-
α in spleen tissue. Previous investigations into the neural circuitry involved in associative 
learning have conclusively revealed the importance of the BLA in the expression of 
conditioned responses. However, results previously discussed indicating that the amygdala is 
not involved in the expression of cyclosporine A-conditioned immunosuppression of 
lymphocyte proliferation, IL-2, and interferon-γ conflict with well-established evidence 
supporting the involvement of the amygdala in conditioned responding. Methodological 
differences may explain the inconsistent results. It has been suggested that the route of 
administration of a CS may have an effect on the outcome of the experimental manipulation. 
For example, in one study investigators sought to determine if either passive intraoral 
administration of saccharin or voluntary saccharin administration via a bottle followed by the 
pairing of LiCl affected the expression of CTA. Results of the study indicated that when 
21 
conditioning is performed using a bottle, the amygdala is not involved. However, when 
experimenters conditioned animals using intraoral administration of the CS, the amygdala 
was found to be required for CTA learning (Schafe, Thiele et al. 1998).  It was suggested that 
the lack of continuity with previous findings may be due to intraoral and bottle 
administration of the CS facilitating different types of learning, Pavlovian and instrumental, 
which activate different neural pathways. This could possibly explain the study by Pacheco-
Lopez and colleagues (2005) suggesting that the amygdala isn’t involved in the expression of 
conditioned immunomodulation, as they used the bottle self-administration method to deliver 
the CS. It is noteworthy that, of the two administration methods, intraoral administration is 
most analogous to the contextual conditioning in the current study insofar that there is no 
response requirement in either procedure, and the findings agree with previous research in 
our laboratory regarding the involvement of the amygdala in heroin-conditioned 
immunomodulation. Furthermore, Lopez and colleagues used an immunosuppressive drug as 
the unconditioned stimulus compared to the use of heroin in the current study. It is known 
that heroin readily passes through the blood-brain barrier and activates pathways throughout 
the brain; however, cyclosporine A does not cross the blood-brain barrier. Therefore, the 
results cannot be directly compared to the current study due to the use of an 
immunosuppressive drug as a CS that is limited to the peripheral nervous system compared 
to the use of centrally and peripherally acting opiate as a CS. 
Future studies will examine the contribution of dopamine in brain regions involved in 
context-reward associations, such as the hippocampus. We have shown that inactivation or 
inhibition of IL-1β cytokine expression in the dorsal hippocampus (DH) prevents heroin-
conditioned immunosuppression of LPS-induced nitric oxide production (Szczytkowski, 
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Lebonville et al. 2013), and it’s possible that the interactions between the DH and the VTA 
are bidirectional. In support of this, D1-like dopamine receptor stimulation in the DH is 
required for the drug context-induced reinstatement of cocaine-seeking behavior (Xie and 
Fuchs, in prep).  Furthermore, a bi-synaptic functional circuit conveys information from the 
CA3 region of the dorsal hippocampus to the anterior VTA (Luo, Tahsili-Fahadan et al. 
2011) via the lateral septum (LS). As a result, GABA agonist-induced inactivation of the LS 
attenuates excitatory and inhibitory neuronal firing in the VTA following CA3 stimulation. 
In addition, inactivation of the CA3, as well as the LS, impairs drug context-induced 
reinstatement of cocaine-seeking behavior. Luo and colleagues propose that activation of 
CA3 glutamatergic pyramidal neurons results in the disinhibition of VTA dopamine neurons 
via this circuit, thus contributing to the expression of context-reward associations. 
Based on our prior work, it is evident that immune alterations that result from 
exposure to drug-associated cues are complex, involving not only the central nervous system 
but the neuroendocrine system and the sympathetic branch of the autonomic nervous system. 
Further efforts must be made to elucidate the neural mechanisms that control these effects in 
order to adequately understand the health consequences associated with opiate use and 
properly protect and treat susceptible populations. 
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